Hang zhao

Dr. Hang zhao


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
GCGuangyong Chen
Guangyong Chen
ZCZhuo Chen
Zhuo Chen
HZHang zhao
Hang zhao
The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain. The role of microRNAs has been implicated in tumour inhibition or activation. In several cancers, the Six1 signalling pathway has been found to be aberrant and also relates to the formation of tumours. We analysed the database for expression profiles and clinical specimens of various grades of glioma to assess microRNA‐155‐3p (miR‐155‐3p) expression. The role of miR‐155‐3p in glioblastoma, cell cycle, proliferation, apoptosis and resistance to temozolomide was assessed in vitro through flow cytometry and cell proliferation assays . Bioinformatics analyses, and assays using luciferase reporter, and immunoblotting revealed that miR‐155‐3p targets Six1 and that the relationship between glioma and healthy brain tissues was significantly inverse. In rescue experiments, overexpressed Six1 revoked the changes in cell cycle distribution, proliferation and resistance to temozolomide estimated by apoptosis induced by overexpressed miR‐155‐3p. MiR‐155‐3p inhibition reduced glioma cell growth and proliferation in the brain of a mouse model and increased the survival of mice with gliomas. Thus, miR‐155‐3p modulates Six1 expression and facilitates the progression of glioblastoma and resistance to temozolomide and may act as a novel diagnostic biomarker and a target for glioma treatment.

28 June 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
ZCZhuo Chen
Zhuo Chen
GCGuangyong Chen
Guangyong Chen
HZHang zhao
Hang zhao
Glioma is one of the most lethal tumours and common malignant in the central nervous system (CNS), which exhibits diffuse invasion and aggressive growth. Several studies have reported the association of FDPS to tumour development and progression. However, the role of FDPS in progression of glioma and macrophage recruitment is not well‐elucidated. In the current study, a remarkable enhancement in FDPS level was observed in glioma tissues and associated with poor prognosis, contributed to tumour growth. FDPS was correlated with macrophage infiltration in glioma and pharmacological deletion of macrophages largely abrogated the oncogenic functions of FDPS in glioma. Mechanistically, FDPS activated Wnt/β‐catenin signalling pathway and ultimately facilitates macrophage infiltration by inducing CCL20 expression. In conclusion, overexpressed FDPS exhibits an immunomodulatory role in glioma. Therefore, targeting FDPS may be an effective therapeutic strategy for glioma.

10 July 2023 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
ZLZhaohui Li
Zhaohui Li
YGYufei Gao
Yufei Gao
JZJinnan Zhang
Jinnan Zhang
LHLiang Han
Liang Han
HZHang zhao
Hang zhao
Meningioma, one of the most common primary central nervous system tumors, are classified into three grades by the World Health Organization (WHO) based on histopathology. The gold-standard treatment, surgical resection, is hampered by issues such as incomplete resection in some cases and a high recurrence rate. Alongside genetic alterations, DNA methylation, plays a crucial role in progression of meningiomas in the occurrence and development of meningiomas. The epigenetic landscape of meningioma is instrumental in refining tumor classification, identifying robust molecular markers, determining prognosis, guiding treatment selection, and innovating new therapeutic strategies. Existing classifications lack comprehensive accuracy, and effective therapies are limited. Methylated DNA markers, exhibiting differential characteristics across varying meningioma grades, serve as invaluable diagnostic tools. Particularly, combinatorial methylated markers offer insights into meningioma pathogenesis, tissue origin, subtype classification, and clinical outcomes. This review integrates current research to highlight some of the most promising DNA and promoter methylation markers employed in meningioma diagnostics. Despite their promise, the development and application of DNA methylation biomarkers for meningioma diagnosis and treatment are still in their infancy, with only a handful of DNA methylation inhibitors currently clinically employed for meningioma treatment. Future studies are essential to validate these markers and ascertain their clinical utility. Combinatorial methylated DNA markers for meningiomas have broad implications for understanding tumor development and progression, signaling a paradigm shift in therapeutic strategies for meningiomas.

13 November 2020 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
HZHang zhao
Hang zhao
ZCZhuo Chen
Zhuo Chen
LXLi-Juan Xie
Li-Juan Xie
GLGuifeng Liu
Guifeng Liu
The original version of this article unfortunately has errors and should be corrected.

27 July 2024 in BMC Immunology
Verified
Journal Article
Open access
PDF file
XJXingyi Jin
Xingyi Jin
ZQZhigang Qin
Zhigang Qin
HZHang zhao
Hang zhao
Background: Glioblastoma is characterized by high aggressiveness, frequent recurrence, and poor prognosis. Histone acetylation-associated genes have been implicated in its occurrence and development, yet their predictive ability in glioblastoma prognosis remains unclear. Results: This study constructs a histone acetylation risk model using Cox and LASSO regression analyses to evaluate glioblastoma prognosis. We assessed the model’s prognostic ability with univariate and multivariate Cox regression analyses. Additionally, immune infiltration was evaluated using ESTIMATE and TIMER algorithms, and the SubMAP algorithm was utilized to predict responses to CTLA4 inhibitor. Multiple drug databases were applied to assess drug sensitivity in high- and low-risk groups. Our results indicate that the histone acetylation risk model is independent and reliable in predicting prognosis. Conclusions: Low-risk patients showed higher immune activity and longer overall survival, suggesting anti-CTLA4 immunotherapy suitability, while high-risk patients might benefit more from chemotherapy. This model could guide personalized therapy selection for glioblastoma patients.

25 October 2017 in Chemical Research in Chinese Universities
Verified
Journal Article
Open access
PDF file
JSJing Su
Jing Su
MYMingyue Yu
Mingyue Yu
ZLZhen Lin
Zhen Lin
HZHang zhao
Hang zhao
HLHaiyan Liu
Haiyan Liu
Zinc oxide nanoparticles(ZnO NPs) are among the most commonly utilized nanomaterials. They are used in a wide range of applications, including medicine, sunscreens, cosmetics, paints, catalysis, electronics, as well as biosensors, and hence, it is crucial to illustrate their biological effects and risks. In the present study, the effects and mechanism of ZnO NPs(≤5 nm) were investigated in rat glioma C6 cells in vitro. The results of transmission elec-tron microscopy(TEM) and X-ray diffraction(XRD) show that ZnO NPs are pure with a uniform diameter of ca. 5 nm. 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide(MTT) assays on C6 cells show that ZnO NPs, at dif-ferent concentrations(0―5 μg/mL), can induce significant cytotoxicity in C6 cells in a dose-dependent manner. An increased level of reactive oxygen species(ROS), a decreased level of glutathione(GSH), and an elevated level of glutathione disulfide(GSSG) and the toxicity mechanism are primarily attributed to the induced cellular oxidative stress. 4′,6-Diamidino-2-phenylindole(DAPI) staining was used to observe the apoptosis. The results show that C6 cells treated with the ZnO NPs at various concentrations(0, 1.25, 2.5 and 5 μg/mL) can induce apoptosis in a dose-dependent manner. These results suggest that ZnO NPs are the killers of the rat glioma C6 cells, and oxidative stress is the underlying mechanism of this process.